Revenue: As of FY2026 Q1, the actual value is USD 7.084 M.EPS: As of FY2026 Q1, the actual value is USD -0.09.EBIT: As of FY2026 Q1, the actual value is USD -675 K.<h4>Segment Revenue</h4><ul><li>Total Revenues: Increased to $7,084,000 for the three-month period ended March 31, 2026, from $6,112,000 in the prior year, an increase of $972,000.</li><li>Leasing Segment Revenue: Increased to $3,020,000 for the three-month period ended March 31, 2026, from $2,991,000 in the prior year, an increase of $29,000, driven by a higher number of Gamma Knife and PBRT procedures.<ul><li>PBRT Services Revenue: Increased to $1,956,000 for the three-month period ended March 31, 2026, from $1,642,000 in the prior year, due to higher procedure volumes.</li></ul></li><li>Direct Patient Services Segment Revenue: Increased to $4,064,000 for the three-month period ended March 31, 2026, from $3,121,000 in the prior year, an increase of $943,000, due to a higher number of procedures at the RI facilities and the Puebla radiation therapy facility.<ul><li>Radiation therapy revenue (RI facilities and Puebla): $2,920,000 for the three-month period ended March 31, 2026, compared to $2,374,000 in the prior year.</li></ul></li><li>Gamma Knife Revenue: Increased to $2,208,000 for the three-month period ended March 31, 2026, from $2,096,000 in the prior year, due to increased procedure volume from the direct patient services segment, offset by lower volume from the leasing segment.</li></ul><h4>Operational Metrics</h4><ul><li>Gross Margin: Increased to $1,288,000 for the three-month period ended March 31, 2026, from $942,000 in the prior year.</li><li>Operating Loss: Improved to -$924,000 for the three-month period ended March 31, 2026, from -$1,299,000 in the prior year.</li><li>Net Loss: Increased to -$962,000 for the three-month period ended March 31, 2026, from -$912,000 in the prior year.</li><li>Net Loss Attributable to American Shared Hospital Services: Decreased to -$612,000 for the three-month period ended March 31, 2026, from -$625,000 in the prior year.<ul><li>Leasing Segment Net Loss: Improved to -$156,000 for the three-month period ended March 31, 2026, from -$303,000 in the prior year.</li><li>Direct Patient Services Segment Net Loss: Increased to -$456,000 for the three-month period ended March 31, 2026, from -$322,000 in the prior year, driven by higher operating costs.</li></ul></li><li>Total Costs of Revenue: Increased to $5,796,000 for the three-month period ended March 31, 2026, from $5,170,000 in the prior year.<ul><li>Maintenance and supplies and other direct operating costs, related party: Increased by $200,000 to $1,061,000 for the three-month period ended March 31, 2026, from $861,000 in the prior year, due to maintenance for LINACs in Puebla and Rhode Island, and the PBRT maintenance contract.</li><li>Depreciation and Amortization: Decreased to $1,289,000 for the three-month period ended March 31, 2026, from $1,445,000 in the prior year, due to the expiration of a Gamma Knife customer contract, replaced Gamma Knife equipment in Peru, and fully depreciated assets in Rhode Island.<ul><li>Leasing Segment Depreciation, amortization, and other expense: $859,000 (2026) vs. $899,000 (2025).</li><li>Direct Patient Services Segment Depreciation, amortization, and other expense: $435,000 (2026) vs. $550,000 (2025).</li></ul></li><li>Other Direct Operating Costs: Increased to $3,446,000 for the three-month period ended March 31, 2026, from $2,864,000 in the prior year, primarily due to higher operating costs at the RI facilities.</li></ul></li><li>Selling and Administrative Expense: Increased to $1,910,000 for the three-month period ended March 31, 2026, from $1,808,000 in the prior year, primarily due to audit, tax, and consulting fees, offset by lower legal fees.</li><li>Interest Expense: Decreased to $302,000 for the three-month period ended March 31, 2026, from $433,000 in the prior year, due to a lower average principal balance on debt.<ul><li>Leasing Segment Interest Expense: $285,000 (2026) vs. $398,000 (2025).</li><li>Direct Patient Services Segment Interest Expense: $17,000 (2026) vs. $35,000 (2025).</li></ul></li><li>Income Tax Expense (Benefit): Increased to an expense of $92,000 for the three-month period ended March 31, 2026, compared to a benefit of -$323,000 in the prior year, primarily due to profits generated in foreign jurisdictions within the direct patient services segment.<ul><li>Leasing Segment Income Tax Expense (Benefit): -$40,000 (2026) vs. -$257,000 (2025).</li><li>Direct Patient Services Segment Income Tax Expense (Benefit): $132,000 (2026) vs. -$66,000 (2025).</li></ul></li></ul><h4>Cash Flow</h4><ul><li>Net Cash Provided by Operating Activities: $2,149,000 for the three-month period ended March 31, 2026, compared to $2,503,000 in the prior year.</li><li>Net Cash Used in Investing Activities: -$41,000 for the three-month period ended March 31, 2026, compared to -$4,015,000 in the prior year.</li><li>Net Cash (Used in) Provided by Financing Activities: -$597,000 for the three-month period ended March 31, 2026, compared to $1,728,000 in the prior year.</li><li>Cash, Cash Equivalents, and Restricted Cash at End of Period: $5,223,000 as of March 31, 2026, compared to $11,491,000 as of March 31, 2025.</li></ul><h4>Unique Metrics</h4><ul><li>PBRT Fractions: Increased to 1,003 for the three-month period ended March 31, 2026, from 831 in the prior year.</li><li>Gamma Knife Procedures: Increased to 229 for the three-month period ended March 31, 2026, from 208 in the prior year.<ul><li>Leasing Segment Gamma Knife Procedures: Decreased by 10.1% for the three-month period ended March 31, 2026, due to the expiration of one customer contract in April 2025.</li><li>Direct Patient Services Segment Gamma Knife Procedures (International): Increased by 44% for the three-month period ended March 31, 2026, with Ecuador volumes increasing by 49%.</li></ul></li><li>Radiation Therapy Procedures (RI facilities and Puebla): 6,311 for the three-month period ended March 31, 2026, compared to 6,726 in the prior year.</li></ul><h4>Future Outlook and Strategy</h4>The company has commitments to purchase and install two Esprit and two LINAC systems totaling $7,884,000 as of March 31, 2026, with installations anticipated in late 2026 or later, which it intends to finance but cannot guarantee acceptable terms or availability. Additionally, the company has service commitments for its equipment totaling $5,705,000 as of March 31, 2026, which it expects to cover with cash flow from operations and cash on hand. The company is in default on its Credit Agreement with Fifth Third Bank and potentially on its DFC Loan, raising substantial doubt about its ability to continue as a going concern due to the risk of accelerated payment obligations that it would be unable to satisfy.

American Shared Hosp | 10-Q: FY2026 Q1 Revenue: USD 7.084 M